Technical Analysis for RCKT - Rocket Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Spinning Top | Other | -6.47% | |
Shooting Star Candlestick | Bearish | -6.63% | |
180 Bearish Setup | Bearish Swing Setup | -6.63% | |
Oversold Stochastic | Weakness | -6.63% | |
Slingshot Bearish | Bearish Swing Setup | -7.42% | |
Crossed Above 200 DMA | Bullish | -7.42% | |
Stochastic Buy Signal | Bullish | -7.42% | |
Oversold Stochastic | Weakness | -7.42% | |
Fell Below 200 DMA | Bearish | -3.07% | |
Down 3 Days in a Row | Weakness | -3.07% |
Alert | Time |
---|---|
Fell Below Lower Bollinger Band | about 5 hours ago |
60 Minute Opening Range Breakdown | about 5 hours ago |
Down 5% | about 5 hours ago |
Lower Bollinger Band Support | about 5 hours ago |
Down 3% | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Rocket Pharmaceuticals, Inc. Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immune System Bone Heart Failure Anemia Bone Marrow Cancer Research Blood Cells Red Blood Cell Genetic Disorder Petros Fanconi Anemia Pyruvate Kinase Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.53 |
52 Week Low | 14.89 |
Average Volume | 744,411 |
200-Day Moving Average | 23.06 |
50-Day Moving Average | 26.89 |
20-Day Moving Average | 24.75 |
10-Day Moving Average | 23.89 |
Average True Range | 1.11 |
RSI (14) | 39.02 |
ADX | 19.02 |
+DI | 15.48 |
-DI | 22.73 |
Chandelier Exit (Long, 3 ATRs) | 24.39 |
Chandelier Exit (Short, 3 ATRs) | 25.64 |
Upper Bollinger Bands | 27.13 |
Lower Bollinger Band | 22.38 |
Percent B (%b) | 0.26 |
BandWidth | 19.17 |
MACD Line | -0.98 |
MACD Signal Line | -0.97 |
MACD Histogram | -0.0083 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.03 | ||||
Resistance 3 (R3) | 25.08 | 24.66 | 24.80 | ||
Resistance 2 (R2) | 24.66 | 24.30 | 24.64 | 24.72 | |
Resistance 1 (R1) | 24.15 | 24.08 | 23.94 | 24.10 | 24.64 |
Pivot Point | 23.73 | 23.73 | 23.62 | 23.70 | 23.73 |
Support 1 (S1) | 23.21 | 23.37 | 23.00 | 23.16 | 22.62 |
Support 2 (S2) | 22.79 | 23.15 | 22.77 | 22.54 | |
Support 3 (S3) | 22.28 | 22.79 | 22.46 | ||
Support 4 (S4) | 22.23 |